AUTHOR=Khaity Abdulrhman , Mostafa Al-dardery Nada , Albakri Khaled , Abdelwahab Omar A. , Hefnawy Mahmoud Tarek , Yousef Yaman A. S. , Taha Ruaa E. , Swed Sarya , Hafez Wael , Hurlemann Rene , Elsayed Mohamed E. G. 

TITLE=Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis

JOURNAL=Frontiers in Psychiatry

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1153648

DOI=10.3389/fpsyt.2023.1153648

ISSN=1664-0640

ABSTRACT=<sec><title>Aims</title><p>We performed this meta-analysis to evaluate the efficacy and safety of glucagon-like peptide-1 receptor-agonists (GLP-1RA) treatment on cardio-metabolic parameters among antipsychotic-treated patients with schizophrenia.</p></sec><sec><title>Methods</title><p>We searched the Web of Science, Cochrane Central Register of Controlled Trials, PubMed, PsycINFO, and Scopus for relevant Randomized Clinical trials (RCTs) from inception until 1 August 2022. Documents were screened for qualified articles, and all concerned outcomes were pooled as risk ratios (RR) or mean difference (MD) in the meta-analysis models using Review Manager (RevMan version 5.4).</p></sec><sec><title>Results</title><p>Pooling data from 7 RCTs (398 patients) showed that GLP-1 RA was superior to placebo with regard to body weight [MD = - 4.68, 95% CI (-4.90,−4.46), <italic>P</italic> &lt; 0.00001], waist circumference [MD = - 3.66, 95% CI (-3.89,−3.44), <italic>P</italic> &lt; 0.00001], body mass index (BMI) [MD = - 1.09, 95% CI (-1.25,−0.93), <italic>P</italic> &lt; 0.00001], systolic blood pressure (SBP) [MD = - 3.07, 95% CI (-3.61,−2.53), <italic>P</italic> &lt; 0.00001], and diastolic blood pressure (DBP) [MD = - 2.02, 95% CI (-2.42,−1.62), <italic>P</italic> &lt; 0.00001]. The total effect did not favor either of the two groups with respect to insulin and respiratory adverse events {[MD = - 0.06, 95% CI (-0.36, 0.24), <italic>p</italic> = 0.70], [RR = 0.66, 95% CI (0.31, 1.40), <italic>p</italic> = 0.28]; respectively}.</p></sec><sec><title>Conclusion</title><p>Our analysis revealed that GLP-1 RA treatment is safe and effective on cardio-metabolic parameters over control in antipsychotic-treated patients with schizophrenia. Nevertheless, the present evidence is not sufficient to confirm the safety and efficacy of GLP-1RA treatment on insulin and respiratory adverse events. Therefore, further studies are recommended.</p></sec><sec><title>Systematic review registration</title><p><ext-link ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022333040" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.crd.york.ac.uk/PROSPERO/</ext-link>, identifier: CRD42022333040.</p></sec>